Licensing Agreements: Key Terms Every Licensee Should Review

A licensing agreement is a contract in which the owner of intellectual property (the licensor) grants another party (the licensee) the right to use that IP under defined conditions — without transferring ownership. Licensing is the primary mechanism through which IP rights are commercially exploited: software is licensed, not sold; films are licensed to distributors; patents are licensed to manufacturers; trademarks are licensed to franchisees and brand partners. The global IP licensing market generates over $300 billion in annual royalty revenues, and the terms of individual license agreements determine how that value is allocated between licensors and licensees.

License vs. Assignment — The Critical Distinction. A license grants a right to use IP while the licensor retains ownership. An assignment permanently transfers ownership of the IP to the assignee under 35 U.S.C. § 261 (patents), 17 U.S.C. § 204 (copyrights require written instrument), and applicable state law (trademarks, trade secrets). The difference is legally and economically significant. An assignee owns the IP and can modify it, relicense it, sell it, or enforce it independently. A licensee merely has the contractual right to use the IP within the scope and duration of the license agreement. Courts strictly enforce this distinction: in Speedplay, Inc. v. Bebop, Inc. (9th Cir. 2000), the court held that a license that purported to grant "all rights" to the licensee still did not constitute an assignment in the absence of a formal written transfer instrument, leaving the licensee without the ability to enforce the patents independently. If the licensor goes bankrupt, a licensee's rights may be at risk under 11 U.S.C. § 365(n), which — for certain IP categories — allows the licensee to elect to retain its license rights despite the licensor's rejection of the agreement in bankruptcy.

Types of IP That Can Be Licensed. Virtually every category of intellectual property can be licensed: - Patents: The right to make, use, sell, offer for sale, and import a patented invention (35 U.S.C. § 271). Patent licenses define which specific rights are granted (e.g., make and use but not sell), for which territory, and whether improvements are included. Patent licenses frequently include most-favored-licensee (MFL) clauses guaranteeing the licensee will not be disadvantaged by more favorable terms granted to later licensees. - Trademarks: The right to use a brand name, logo, or trade dress in connection with specified goods and services under the Lanham Act (15 U.S.C. § 1051 et seq.). Trademark licenses require quality control by the licensor to avoid a "naked license" that can result in trademark abandonment under Barcamerica Int'l USA Trust v. Tyfield Importers, Inc. (9th Cir. 2002). - Copyrights: The right to reproduce, display, distribute, perform, or create derivative works from protected expression (17 U.S.C. § 106). Copyright licenses can be exclusive or non-exclusive and may cover one or all of the exclusive rights. Exclusive licenses in copyright must be in writing per 17 U.S.C. § 204(a); oral copyright licenses are only non-exclusive. - Trade Secrets: The right to use confidential business information — formulas, methods, processes — that derives economic value from secrecy. Trade secret licenses are governed by the Defend Trade Secrets Act (DTSA, 18 U.S.C. § 1836) and applicable state law (usually the Uniform Trade Secrets Act). Licenses must include robust confidentiality obligations to preserve the secrecy that gives the information its legal protection under Kewanee Oil Co. v. Bicron Corp. (1974). - Software: Often licensed under both copyright (the code expression) and, potentially, patent protection (patented algorithms or methods). Software licenses may be subscription-based, perpetual, per-seat, enterprise-wide, or usage-based (consumption pricing for cloud/SaaS).

The Licensor Always Retains Something. Unlike a sale, a license creates an ongoing relationship. The licensor retains the right to enforce the IP against third parties, to grant additional licenses (unless the agreement is exclusive), and to receive royalties or license fees. The licensee's rights exist only for as long as the license agreement remains in effect and only within the scope defined in the agreement. This is why the grant clause — the contractual sentence that creates the licensee's rights — is the most important provision in any license agreement and must be parsed with precision.

The type of license granted — exclusive, non-exclusive, or sole — is the single most economically significant term in a licensing agreement. It determines whether the licensee is the only market participant with rights to the IP, whether the licensor can compete with the licensee, and what the license is worth in both commercial and legal terms.

Exclusive License. An exclusive license means that only the licensee can exercise the licensed rights within the defined scope (field of use, territory, and duration). The licensor cannot grant additional licenses to third parties and — critically — cannot itself practice the IP within that exclusive scope. Exclusive licenses command higher royalties because they give the licensee a competitive advantage: typically 2-5x the rate of a comparable non-exclusive license in technology sectors. Under U.S. patent law, an exclusive licensee who receives all substantial rights in a patent typically has standing to sue infringers independently — or must be joined as a co-plaintiff with the licensor — which is legally significant for enforcement. The leading case, Waterman v. Mackenzie (1891), established the standing rules still applied today. More recently, WiAV Solutions LLC v. Motorola, Inc. (Fed. Cir. 2010) clarified that an exclusive licensee must join the patent owner in infringement suits unless the licensee holds all substantial rights.

Non-Exclusive License. A non-exclusive license permits the licensor to license the same IP to multiple parties simultaneously, including the licensee's competitors. Most software, content, and standard technology licenses are non-exclusive. The licensee gets the right to use the IP but gains no competitive exclusivity from it. Royalty rates for non-exclusive licenses are typically lower — often 0.5-3% of net sales for non-exclusive patent licenses in technology, versus 3-10% or more for exclusive licenses. A critical risk: a licensor may grant dozens of non-exclusive licenses, reducing the market value of the licensed IP and the licensee's competitive position while the licensee continues paying royalties.

Sole License. A "sole" license is a middle position: the licensor agrees not to grant licenses to any other third party within the scope, but retains the right to practice the IP itself. A sole license gives the licensee exclusivity against third-party competition but does not prevent the licensor from competing directly. This distinction is critical if the licensor is a direct competitor of the licensee or plans to commercialize the same technology independently.

Field-of-Use Restrictions. A field-of-use limitation confines the license to a specific market segment or application. For example, a patent covering a polymer compound might be licensed to Company A for medical device applications and Company B for automotive applications. Field-of-use restrictions are generally enforceable under U.S. patent law — the Supreme Court upheld their validity in General Talking Pictures Corp. v. Western Electric Co. (1938), and the principle remains good law. Field-of-use licenses allow licensors to segment markets and maximize total royalty income across multiple licensees. Licensees should carefully define the field of use broadly enough to cover current and reasonably anticipated future products, while recognizing that the licensor will seek the narrowest definition possible to preserve optionality for other licensees.

Territory. Most license agreements are geographically limited. A licensee may have rights in the U.S. but not Europe, or worldwide rights with country-specific royalty rates. Territory definitions matter for distribution agreements, where a licensee may need rights in specific countries to sell licensed products. Carve-outs — geographic areas where the licensor retains rights or has granted to other parties — should be mapped against the licensee's actual and projected business. "Rest of world" licenses with country-specific exclusions are common in pharmaceutical and entertainment licensing.

Sublicensing Rights. Unless the license agreement expressly grants sublicensing rights, the licensee generally cannot grant sublicenses to third parties. Sublicensing rights are commercially important for software vendors (who need to sublicense embedded components to end users), distributors (who need to pass through rights to customers), and technology platform companies. The clause above requires licensor consent — common but negotiable. Negotiate for a right to sublicense to affiliates without consent, and for a "not unreasonably withheld" standard for third-party sublicenses. Also address whether sublicensing revenue from sub-licensees is treated as Net Sales or subject to a separate royalty rate.

Cross-Licensing. In technology-heavy industries (semiconductors, telecommunications, automotive, mobile), companies often hold large patent portfolios and license to each other reciprocally. A cross-license grants each party rights under the other's patents, often for zero royalties or reduced rates — reducing litigation risk between technology peers. Cross-licenses between IBM and Hewlett-Packard, Intel and ARM, and major telecommunications companies form the backbone of the modern technology industry's IP ecosystem. Key cross-license issues: scope (which patents, which products, which specific rights), term, treatment of future patents acquired after the cross-license is signed, and whether a party's acquisition by a third company terminates or modifies the cross-license (change-of-control provisions).

The grant clause and royalty structure are the core economic terms of any license agreement. Getting them right requires precise drafting of both the rights granted and the financial obligations that flow from those rights. Underestimating the complexity of royalty structures is one of the most common and costly mistakes licensees make.

The Grant Clause — What Rights Are Actually Transferred. The grant clause should specify: (1) the type of license (exclusive, non-exclusive, sole); (2) the specific IP licensed (identified by patent number, trademark registration, copyright registration, or detailed description — vague IP descriptions create litigation); (3) the licensed acts (make, use, sell, offer for sale, import, reproduce, display, distribute, create derivative works — each right matters separately, especially for patent licenses where 35 U.S.C. § 271 makes each act independently infringing); (4) the field of use; and (5) the territory. Any right not expressly granted in the grant clause is reserved to the licensor. The maxim from the Supreme Court in Quanta Computer, Inc. v. LG Electronics, Inc. (2008) applies broadly: IP licensors can broadly restrict the scope of rights through clear license language.

Scope of Use — "Licensed Products" and "Licensed Uses" Definitions. The grant clause's economic scope depends heavily on how "licensed products" and "licensed uses" are defined. A royalty-bearing license typically defines what products or services fall within the royalty base. A narrow definition may exclude future product lines the licensee develops using the licensed IP; a broad definition may require royalty payments on products the licensee developed independently. Draft the definition to cover all products reasonably expected to use the licensed IP while carving out clearly independent products. The Federal Circuit's decision in Lucent Technologies, Inc. v. Gateway, Inc. (2009) illustrates how courts analyze the scope of "licensed products" when patent claims are broad: the entire market value rule can dramatically expand the royalty base if the licensed IP drives demand for a multi-component product.

Royalty Structures — Five Primary Models. Licensing royalties take several forms: - Running royalty (percentage of net sales): The most common structure — a percentage of the licensee's revenue from licensed products. Typical rates: 1-5% for non-exclusive technology patent licenses; 3-10% for exclusive technology licenses; 5-15% for pharmaceutical licenses; 10-18% for entertainment merchandising. Simple in concept but complex in implementation due to the Net Sales definition. - Flat fee (lump sum): A fixed payment at signing or in installments, regardless of the licensee's sales performance. Appropriate when the IP's value is fixed and predictable. Licensees prefer lump-sum licenses when they project high revenue; licensors prefer them when they want immediate cash and distrust the licensee's royalty reporting. - Per-unit royalty: A fixed amount per unit sold or licensed. Common in pharmaceutical licensing where unit pricing varies widely but volume is the key commercial metric. E.g., $0.25 per unit for a component patent on a mass-market product. - Milestone payments: One-time payments triggered by specific development or commercial events — IND filing ($5M), Phase II completion ($10M), NDA approval ($25M), first commercial sale ($15M), annual sales exceeding $100M ($20M). Common in pharmaceutical and biotech licensing where the licensee undertakes development risk over 8-15 years. - Minimum annual guarantee (MAG): A floor royalty payment due regardless of actual sales. Protects the licensor from the licensee "sitting on" the license without commercializing it. The clause above illustrates a non-stackable MAG: excess royalties in a high-revenue year cannot offset the MAG in future years.

Net Sales Definition — The Devil in the Details. The Net Sales definition determines the royalty base and is frequently a major negotiation point. Licensors prefer broad definitions; licensees prefer narrow definitions excluding discounts, returns, shipping, taxes, insurance, and other cost items. Common battlegrounds: (1) Whether "bundled" products sold as a package require allocation to determine the licensed-product portion; (2) Whether related-party sales (to affiliates) are included at list price or actual transfer price; (3) Whether currency conversion for international sales creates royalty variation; (4) Whether sublicensing revenue received from sub-licensees is treated as Net Sales (subject to the full royalty rate) or subject to a separate, lower royalty rate (typically 20-50% of running royalties). The difference between a broad and narrow Net Sales definition can shift effective royalty rates by 15-25% even at the same stated percentage.

Payment Terms, Reporting, and Audit Rights. Running royalties are typically reported quarterly with payment within 30-60 days of quarter end. The license agreement should specify: the currency of payment; the applicable exchange rate for international sales (spot rate at end of quarter is common); interest on late payments (typically prime rate plus 2-3%); and the royalty report format. Audit rights allow the licensor to inspect the licensee's books and records to verify royalty accuracy. Standard audit provisions allow audits once per year upon 30-60 days written notice, at licensor's expense unless the audit reveals an underpayment exceeding 5-10% (in which case the licensee pays audit costs). A most-favored-licensee clause may guarantee that if the licensor later grants any other party a lower royalty rate for the same rights, the licensee's rate is automatically reduced to match.

IP ownership provisions determine who owns the value created during the license relationship — and whether the licensee's own innovations may be captured by the licensor. These provisions require careful attention, particularly when the licensee is contributing substantial development resources. Improvement clauses in technology and pharmaceutical licenses are among the most heavily negotiated provisions and can determine whether a licensee's multi-year R&D program benefits the licensor's portfolio instead of the licensee's competitive position.

Background IP and Foreground IP. "Background IP" refers to IP that each party brings to the relationship — existing before the agreement or developed independently outside the scope of the agreement. "Foreground IP" (also called "foreground technology" or "project IP") refers to IP developed during and as part of the license relationship. The agreement should clearly distinguish between the two, and should specify who owns each category. Failure to clearly delineate background IP can create disputes about whether a licensee's pre-existing technology was "brought to" the relationship or "developed under" the license — with significant ownership consequences. This was at issue in Campbell v. General Dynamics Government Systems Corp. (1st Cir. 2005), where ambiguity about background IP ownership led to years of costly litigation.

The Improvement Clause — A Major Risk for Licensees. The clause above is a "grant-back" provision requiring the licensee to assign all improvements to the licensor. This is among the most significant provisions in any license agreement for a licensee making R&D investments. An assignment-based grant-back means the licensee's own innovations become the licensor's property. The licensor then grants the licensee a non-exclusive license back to those innovations — which the licensor can now also license to the licensee's competitors. Many technology companies categorically refuse to sign agreements with assignment-based grant-backs because they transfer the value of the licensee's own R&D budget to the licensor. In the pharmaceutical industry, Kimble v. Marvel Entertainment (2015) confirmed that royalty obligations tied to an improvement grant-back may persist even after patent expiration under Brulotte v. Thys Co. (1964), creating a long-term royalty trap.

Negotiating Grant-Back Provisions. Alternatives to assignment-based grant-backs include: (1) License-back rather than assignment: The licensee licenses improvements to the licensor (rather than assigning them), retaining ownership; (2) Non-exclusive license-back: The licensor gets a non-exclusive license to use licensee improvements, but cannot sub-license them to competitors; (3) No grant-back: The licensee owns its improvements outright with no obligation to the licensor; (4) Mutual grant-back: Both parties grant each other non-exclusive licenses to improvements — more balanced in peer-to-peer technology relationships. Under U.S. antitrust analysis, exclusive grant-backs may raise concerns under the rule of reason when they substantially reduce the incentive for the licensee to innovate, as articulated in the DOJ-FTC Antitrust Guidelines for the Licensing of Intellectual Property (updated 2017). The EU's Technology Transfer Block Exemption Regulation (TTBER) similarly restricts exclusive grant-back obligations in EU licensing.

Jointly Developed IP. When both parties contribute to developing new IP under the license relationship, joint ownership creates significant legal complications. Under U.S. patent law, each co-owner of a patent may independently exploit the patent and grant non-exclusive licenses without accounting to the other co-owner (35 U.S.C. § 262). This was applied in Israel Bio-Engineering Project v. Amgen (Fed. Cir. 2007): a joint patent owner licensed the jointly-held patent to Amgen without the other co-owner's consent, which was held permissible but commercially devastating for the non-consenting co-owner. To avoid this result, license agreements should either (1) vest ownership of jointly developed IP in one party with a license-back to the other, or (2) include explicit restrictions on each joint owner's right to sublicense without the other's consent.

Moral Rights. For copyrighted works, particularly visual art and music, moral rights give authors the right to claim authorship and object to modifications. In the United States, moral rights are limited to works of visual art under VARA (17 U.S.C. § 106A). In Europe, moral rights are broader and cannot be waived by contract in many jurisdictions — they survive the death of the author. International licensing agreements involving creative works — particularly music, film, software UI, or visual art — must address moral rights if the licensee intends to modify or create derivative works, especially for distribution in France, Germany, and other civil law jurisdictions where moral rights are robust.

Quality control provisions are legally mandatory for trademark licenses and commercially important for all IP licenses where the licensor's reputation is connected to the licensee's output. Inadequate quality control in a trademark license can result in the licensor losing its trademark rights entirely — a catastrophic outcome for both parties, since the license itself becomes worthless if the underlying trademark is abandoned.

The Lanham Act and "Naked Licenses." Under federal trademark law (15 U.S.C. § 1051 et seq., the Lanham Act), a trademark owner must maintain quality control over all uses of its trademark by licensees. If a trademark owner licenses its mark without maintaining meaningful quality control, the license is a "naked license" — and a naked license results in abandonment of the trademark. The leading case is Barcamerica Int'l USA Trust v. Tyfield Importers, Inc. (9th Cir. 2002): the Ninth Circuit held that a winery's trademark was abandoned because the licensor had a contractual quality control provision but exercised no actual oversight — relying solely on the licensee's "reputation" rather than conducting inspections or testing. Trademark abandonment is fatal and permanent — the licensor loses the mark entirely, not just in the licensed territory.

What Constitutes Adequate Quality Control. Courts have held that quality control can consist of: (1) explicit quality standards in the license agreement with inspection and audit rights actually exercised; (2) the licensor's actual monitoring of the licensee's goods or services — even informal monitoring may be sufficient if consistent; (3) industry custom and the inherent nature of the business relationship (e.g., a franchisor who conducts regular site visits). Actual monitoring matters: in Taco Cabana Int'l, Inc. v. Two Pesos, Inc. (5th Cir. 1991), the court found adequate quality control where the licensor had approved product specifications and conducted periodic inspections. Licensors should document their quality control activities throughout the license term — keep records of every inspection, approval, and communication regarding quality.

Approval Processes and Timelines. Many trademark licenses require pre-approval of marketing materials, product designs, packaging, and advertising before use. The approval process should specify: (1) what materials require approval (a defined list is better than an open-ended standard); (2) the approval timeline — the clause above uses 15 business days with deemed approval for non-response, a licensee-favorable provision that prevents the licensor from stalling approvals indefinitely; (3) the standards against which approval is evaluated (conformance to quality standards and brand guidelines is more objective than "licensor's sole discretion"); and (4) the consequences of using materials without approval (breach of contract, not necessarily trademark infringement). A deemed-approval provision is critical for licensees who need to operate on commercial timelines.

Inspection Rights — Scope and Limits. Licensor inspection rights should be specified in terms of: (1) notice requirements — the clause above requires "reasonable notice"; negotiate for at least 5-10 business days; (2) frequency — once per year is typical for trademark licenses; quarterly inspections may be appropriate for pharmaceutical or food licenses; (3) scope — physical facilities, products, records, or all of the above; and (4) cost — typically licensor's cost unless the inspection reveals material noncompliance. Resist overly broad inspection rights including unannounced inspections or inspections with unrestricted access to confidential proprietary records. Inspections that could expose trade secrets should be subject to confidentiality provisions.

Quality Control for Non-Trademark IP. While quality control is legally required only for trademark licenses, it is commercially important for other IP licenses where the licensor's reputation is implicated. A pharmaceutical company licensing a branded drug compound has strong quality control interests — FDA Good Manufacturing Practice (GMP) compliance by the licensee is essential to the licensor's FDA standing. Software licensors may require the licensee to meet security standards (SOC 2, ISO 27001, FedRAMP) as a condition of the license. Technology licenses increasingly include audit rights over the licensee's security practices, open-source compliance, and data handling under privacy laws.

Term and termination provisions determine the duration of the licensee's rights and the conditions under which those rights can be ended — prematurely or at term. For a licensee making substantial investments in product development or brand-building based on licensed IP, termination provisions can be commercially existential: the loss of a core IP license can force a product off the market, strand customer commitments, and destroy business value built over years.

License Duration and Alignment with Investment. The initial term should be long enough to allow the licensee to amortize its investment in developing products based on the licensed IP, building brand recognition, and achieving commercial returns. A five-year license may be appropriate for a software license with minimal licensee investment; it is wholly inadequate for a pharmaceutical company investing hundreds of millions of dollars in clinical trials to develop a licensed drug compound. In pharmaceutical licensing, initial terms typically run for the life of the licensed patent — 20 years from filing date under 35 U.S.C. § 154 — with provisions for continuation if patent term extensions are granted. The mismatch between license term and investment recovery horizon is one of the most common and costly mistakes in license negotiations.

Automatic Renewal vs. Affirmative Renewal. Automatic renewal (as in the clause above) reduces the administrative burden of license maintenance but creates renewal risk for both parties: the licensor may find itself locked into an unfavorable term, and the licensee may find rights terminated by inadvertent failure to send a non-renewal notice. Affirmative renewal provisions (requiring the licensee to take action to renew) give the licensor more control but place the administrative burden on the licensee. Whichever structure is used, the renewal notice period (90 days in the clause above) should be clearly specified, and licensees should implement calendar reminders well in advance. Larger organizations should designate a "license manager" whose role includes monitoring renewal deadlines.

Termination for Cause — Cure Period Analysis. Standard termination for cause provisions allow either party to terminate if the other materially breaches and fails to cure within the specified period. Key issues: (1) Does the cure period begin upon notice or upon the breach itself — a significant distinction if notice is delayed? (2) What constitutes a "material" breach — courts interpret this inconsistently, with some requiring a showing that the breach goes to the "essence" of the contract (see Jacob & Youngs, Inc. v. Kent, 1921 N.Y. Court of Appeals); (3) Are there any breaches for which no cure is available (immediate termination grounds), such as insolvency, criminal conviction, or willful IP infringement? (4) Does repeated breach — even if cured each time — give rise to termination rights? Negotiate for 60-90 day cure periods for operational compliance breaches, and resist immediate termination rights for anything other than willful infringement, fraud, or insolvency.

Termination for Convenience — A Major Risk. Some license agreements include a right to terminate for convenience — without cause — upon specified notice. A termination-for-convenience provision held solely by the licensor is an extremely significant risk for a licensee that has built its business around the licensed IP. Licensees should strongly resist one-sided termination-for-convenience provisions; if they cannot be eliminated, structure them with: (1) long notice periods (180-365 days minimum for significant licenses); (2) exit fees payable to the licensee as compensation for stranded investment; and (3) sell-off periods during which the licensee can deplete existing inventory and fulfill outstanding customer commitments.

Post-Termination Obligations — Wind-Down and Sell-Off Rights. Upon termination, licensees typically must: (1) immediately cease all use of the licensed IP; (2) destroy or return all materials embodying the licensed IP; (3) pay all outstanding royalties; and (4) comply with post-termination confidentiality obligations. Licensees should negotiate for: (1) a sell-off period — typically 90-180 days — to deplete existing inventory of licensed products and fulfill existing customer orders; (2) survival of specific contractual provisions (indemnification, accrued royalties, dispute resolution, confidentiality) rather than a blanket "all provisions survive" clause; and (3) an obligation to destroy (not return) electronic embodiments of confidential IP.

Licensor Bankruptcy — 11 U.S.C. § 365(n) Protection. The Bankruptcy Code's § 365(n) protects licensees of certain IP categories (patents, copyrights, and trade secrets) when a licensor files for bankruptcy and rejects the license agreement. Under § 365(n), the licensee may elect to retain its license rights and continue paying royalties, even after the licensor's rejection of the agreement. This was critical in In re Qimonda AG (Bankr. E.D. Va. 2012), where semiconductor patent licensees successfully invoked § 365(n) to retain license rights. However, § 365(n) does not clearly cover trademark licenses — Mission Product Holdings v. Tempnology LLC (S. Ct. 2019) held that rejection of a trademark license does not strip the licensee of trademark rights, but the analysis turned on general rejection principles rather than § 365(n) specifically. Trademark licensees should negotiate for contractual § 365(n)-equivalent protections explicitly.

Licensor warranties determine the legal protection the licensee receives if the licensed IP turns out to be defective, encumbered, or the subject of third-party claims. A licensee that receives strong warranties has contractual recourse; a licensee that accepts an "as is" license bears the full risk of IP validity, ownership, and non-infringement — effectively acting as a self-insurer against IP risks it cannot fully evaluate.

IP Ownership Warranty. The most fundamental licensor warranty is that the licensor actually owns (or has the right to license) the IP being licensed. IP ownership can be unclear for several reasons: chain-of-title defects (an inventor never properly assigned to the company), work-made-for-hire disputes (a contractor who developed the IP may claim co-ownership under Community for Creative Non-Violence v. Reid, 1989), co-invention issues (a collaborator may have joint ownership rights under 35 U.S.C. § 116), or prior assignments the licensor has forgotten or failed to disclose. Licensees relying on licensed IP for core products should request evidence of clean title — patent assignments recorded in the USPTO, copyright registration records at the Copyright Office, or trademark ownership documentation. For software, request confirmation that all key developers signed IP assignment agreements.

Non-Infringement Warranty. A warranty that the licensed IP does not infringe third-party rights is commercially significant but legally complex. Patent non-infringement is difficult to warrant with certainty because patent claims are often interpreted differently by different courts, and new patents may issue that cover existing technology. Licensors often narrow this warranty to their actual knowledge ("to licensor's knowledge, the licensed IP does not infringe...") or limit it to the effective date. In MedImmune, Inc. v. Genentech, Inc. (2007), the Supreme Court allowed a licensee to challenge the validity of the licensed patent while continuing to pay royalties — the licensor's warranty of validity is not treated as a covenant not to challenge. Licensees should understand that a knowledge-qualified warranty provides materially less protection than an unqualified warranty and price their risk accordingly.

No Encumbrances. Encumbrances on IP can take many forms: an existing exclusive license to a third party; a security interest granted to a lender against the IP as collateral (under UCC Article 9, as amended, security interests can be granted in IP including patents, trademarks, and copyrights, with perfection requirements varying by IP type); a government march-in right for federally funded inventions under the Bayh-Dole Act (35 U.S.C. §§ 200-212 — where the federal government retains the right to require licensing of federally funded IP if the IP is not adequately commercialized); or a co-ownership interest. The "no encumbrances" warranty protects the licensee against discovering that the licensor's IP rights are subject to prior claims or restrictions that compromise the value of the license.

Licensor Authority. The warranty that the licensor has authority to enter the agreement is particularly important when the licensor is an entity — the signatory must have actual authority to bind the entity, the entity's organizational documents must permit the transaction, and any required board or shareholder approvals must have been obtained. For technology-company licenses, confirm that the signatory's authority covers the specific IP rights being licensed, not merely the company's general business operations. For university or government-origin IP, additional approvals (technology transfer office, government agency consent) may be required.

Fitness and Merchantability Disclaimers — The "As Is" Trap. The clause above includes a standard disclaimer of implied warranties of fitness for a particular purpose and merchantability. Under UCC Article 2A (leases) and the common law principles applied to license agreements, this disclaimer is usually enforceable if conspicuous. An "as is" limitation means the licensor does not warrant that the licensed IP will produce the results the licensee expects. For a licensee developing products based on licensed technology, this disclaimer can be commercially devastating if the technology turns out to be non-functional, unpatentable, or less capable than represented in pre-contractual discussions. Importantly, under Enzo Biochem, Inc. v. Calgene, Inc. (Fed. Cir. 1999), the enablement requirement of 35 U.S.C. § 112 means a licensed patent must "enable" someone skilled in the art to practice the invention — but this does not guarantee the technology will work for the licensee's specific commercial purpose.

Indemnification and liability provisions allocate the financial risk of claims between licensor and licensee. IP infringement claims — where a third party asserts that the licensed IP infringes its own IP — are the most significant risk in most licensing relationships. Patent litigation in the United States averages $2-5 million in legal fees per side through trial, and a successful damages award can dwarf that figure (e.g., the $1.5 billion verdict in Lucent Technologies v. Gateway, subsequently modified on appeal).

IP Infringement Indemnity — The Core Protection. A licensor IP indemnity means the licensor agrees to defend and pay for any claims that the licensed IP infringes third-party IP rights — when the licensee is using the IP within the licensed scope. This is a critical protection: if the licensor has granted rights that it turns out not to have (because the technology infringes someone else's patent), the licensee should not bear the financial cost of defending and settling the resulting third-party claim. Without an IP indemnity, the licensee would need to defend infringement claims at its own expense (potentially millions of dollars) and then pursue a breach of warranty claim against the licensor for reimbursement — an inefficient, expensive, and uncertain process.

Scope of IP Indemnity — What Is and Is Not Covered. IP indemnities are typically limited: (1) The infringement must arise from the licensee's use within the licensed scope — not from modifications the licensee made to the licensed IP; (2) The licensor's indemnity typically does not cover infringement arising from the combination of licensed IP with third-party products or technology not provided by the licensor (the "combination product" carve-out — critical because many IP infringement claims involve combinations of elements); (3) The licensor often seeks to control the defense strategy and settlement — which may not align with the licensee's business interests, particularly if the licensor would prefer to settle while the licensee wants to challenge the third-party patent; (4) The licensee's failure to provide timely notice of the claim may reduce or eliminate the licensor's indemnity obligation.

Duty to Defend vs. Indemnify — A Critical Distinction. An agreement to "defend, indemnify, and hold harmless" is substantially broader than a mere obligation to indemnify. The duty to defend requires the indemnitor to provide legal defense from the outset of a claim — before liability is determined — rather than merely reimbursing costs after the fact. This practical distinction is significant: a licensor that only indemnifies (but does not defend) forces the licensee to fund its own defense of an IP claim and then seek reimbursement. A licensor that defends provides practical protection from the first demand letter. Negotiate for defense obligations to include the right to select counsel (or at minimum, to approve the licensor's selected counsel) and to participate meaningfully in settlement decisions that affect the licensee's business.

Notice Requirements — A Common Trap. Most IP indemnities require the indemnitee (licensee) to provide prompt written notice of any claim as a condition of the indemnity obligation. The clause above requires notice within 10 business days — a very short window. Failure to provide timely notice can be asserted by the licensor as a basis to deny the indemnity. Negotiate for: (1) longer notice periods (30 days is more realistic); (2) a prejudice standard — the licensor's obligation is reduced (not eliminated) only to the extent the licensor can demonstrate actual prejudice from delayed notice; and (3) a cure period after notice is given before the licensor can assert a notice failure as a complete defense.

Insurance Requirements. Many license agreements require the licensee to maintain: general liability insurance ($1-5M per occurrence), product liability ($5-10M for product companies), errors and omissions/professional liability ($1-2M for service licensees), and sometimes IP infringement insurance (available but expensive — $500K-$5M in annual premiums for meaningful coverage). Verify that the required insurance is available from carriers at commercially reasonable rates, and that the coverage limits reflect realistic risk for your business. Negotiate for the right to self-insure if you can demonstrate financial capacity.

Limitation of Liability — Cap and Exclusions. The clause above illustrates two standard limitations: (1) exclusion of consequential, indirect, and punitive damages — which in licensing disputes often represent the most significant damages (lost profits from being forced off-market); and (2) a liability cap equal to one year's royalties — which may be trivially small for a licensee paying $100K/year in royalties on a license that is enabling a $50M product line. Carve-outs from liability caps and consequential-damages exclusions that should be negotiated include: gross negligence and willful misconduct; fraud and intentional misrepresentation; IP indemnification obligations (the cap should not apply to the licensor's indemnity for the very IP infringement risks the indemnity was meant to cover); confidentiality breaches; and IP ownership warranties. For the liability cap, negotiate for the higher of (a) royalties paid in the preceding 12 months or (b) a stated minimum floor amount.

Licensing agreements are governed by a patchwork of federal IP law and state contract law. The choice of governing law affects: implied license doctrines, trade secret protection standards, non-compete enforceability for IP development staff, implied warranty provisions, and the remedies available for breach. The following table covers ten states where licensing disputes are most frequently litigated.

Federal Preemption — When Federal IP Law Controls. Federal IP law substantially preempts state law in several contexts: (1) Copyright preemption: The Copyright Act (17 U.S.C. § 301) preempts state law claims equivalent to the exclusive rights under copyright — state contract claims for breach of a license agreement are generally not preempted (ProCD, Inc. v. Zeidenberg, 7th Cir. 1996); (2) Patent law: Patent validity, infringement, and enforceability are governed exclusively by federal law under 35 U.S.C. — state contract law governs the license agreement terms but cannot modify patent law defenses; (3) Trade secrets: The Defend Trade Secrets Act (DTSA, 18 U.S.C. § 1836) provides a federal civil cause of action supplementing (not replacing) state trade secret law; (4) Trademark: The Lanham Act governs federal trademark licensing but state trademark laws can also apply to marks registered at the state level.

Patent Exhaustion — First Sale Doctrine. Under the patent exhaustion doctrine (Impression Products, Inc. v. Lexmark International, Inc., S. Ct. 2017), the authorized sale of a patented item exhausts the patent holder's right to control further use or sale of that specific item. License agreements that attempt to restrict downstream use of licensed products after sale — such as post-sale use restrictions and single-use mandates — are typically unenforceable as a matter of patent law, regardless of what the license agreement says.

Licensing agreement structures vary significantly by industry. Key industry-specific issues that materially change the risk profile and economic terms of licensing agreements are summarized below. Using a generic licensing template without addressing industry-specific provisions is one of the most common causes of licensing disputes.

Software and SaaS Licensing. Modern software licensing presents unique issues not present in traditional IP licensing: - SLA (Service Level Agreement): SaaS licenses are effectively service agreements. The SLA specifies uptime commitments (typical tiers: 99.5% = ~44 hours downtime/year; 99.9% = ~9 hours; 99.99% = ~53 minutes), scheduled maintenance windows, incident response times, and the licensee's remedies for SLA failures (typically service credits of 5-30% of monthly fees, often capped at one month's total fee — not actual damages). Licensees should ensure that SLA credits are not the exclusive remedy for sustained, catastrophic, or repeated SLA failures. - Source Code Escrow: If the SaaS platform is critical and the licensor's bankruptcy would cripple the licensee's operations, negotiate for a source code escrow arrangement. The licensor deposits source code with a neutral escrow agent (EscrowTech, Iron Mountain, NCC Group); the licensee gets access upon trigger events (insolvency, cessation of business, material sustained SLA failure). Escrow services cost $1,500-5,000 per year plus a deposit fee. - Open Source Compliance: Enterprise software incorporates open-source components. MIT and BSD licenses are permissive; GPL v2/v3 licenses impose copyleft obligations requiring derivative works to also be released under GPL. Licensees should request an open-source Software Bill of Materials (SBOM) and verify that the licensor's use of open-source components does not impose GPL copyleft obligations on the licensee's own proprietary code. - Data Ownership and Privacy: SaaS agreements must specify who owns data input by the licensee (almost always the licensee), how the licensor can use that data (anonymized aggregation for product improvement is typically permitted; sale to third parties is not), obligations under GDPR, CCPA, and other privacy regulations, and data portability upon termination (the licensor must provide data in a usable format within a reasonable time, typically 30 days).

Entertainment Licensing (Music, Film, Merchandising). Entertainment licenses involve issues specific to creative IP: - Music: Music licensing requires separate licenses for the musical composition (melody and lyrics, typically owned by a publisher) and the master recording (the specific recorded performance, typically owned by a record label or the artist). Synchronization licenses (for use of music in film, TV, or video games) require separate licenses from both copyright owners. Mechanical licenses (reproducing music in physical or digital form) are subject to statutory royalty rates under 17 U.S.C. § 115 — currently $0.091 per copy for songs under 5 minutes. - Film: Film distribution agreements license the right to distribute a film in specified media (theatrical, home video/VOD, streaming, TV, airline) for specified territories and time periods. License fees are often structured as minimum guarantees plus revenue shares. Holdback provisions prevent the licensor from releasing the film in competing media during specified exclusivity windows (e.g., theatrical window of 45-90 days before streaming release). - Merchandising: Trademark licenses for consumer product merchandising (sports team logos, entertainment characters, fashion brands) require robust quality control provisions. Royalty rates for entertainment merchandising typically range from 10-18% of net sales — significantly higher than most technology patent licenses. Minimum guarantees are standard and non-negotiable for major brand licenses.

Technology and Patent Licensing — Validity and FRAND. Patent licensing involves unique considerations: - Patent Validity Challenges: Under Lear, Inc. v. Adkins (1969), licensees generally have the right to challenge patent validity even while paying royalties — licensee estoppel was abolished. However, some license agreements include covenants not to challenge, which are enforceable in some contexts under MedImmune v. Genentech (2007). A licensee should be cautious about agreeing to a covenant not to challenge — it forfeits the right to attack invalid patents in later IPR or district court proceedings. - Standards Essential Patents (SEPs): Patents declared essential to a technical standard (Wi-Fi, 5G, Bluetooth, USB, HEVC) must be licensed on FRAND (Fair, Reasonable, and Non-Discriminatory) terms as a condition of the standard-setting organization's IP policy. FRAND rate disputes are litigated worldwide — in Ericsson, Inc. v. D-Link Systems, Inc. (Fed. Cir. 2014), the court set out the framework for FRAND royalty determination based on the value of the patented contribution to the standard.

Brand and Trademark Licensing. Brand royalties for established consumer brands typically range from 2-15% of net sales, depending on brand strength, exclusivity, and territory. Co-existence agreements define each party's territory and permitted uses when multiple parties use similar marks in different markets.

Pharmaceutical and Biotech Licensing. Drug and biotech licensing is among the most complex and high-stakes: - Development Milestones: Pharma licenses typically structure payments as upfront fees ($5-50M) plus milestone payments tied to clinical development stages (IND filing, Phase I/II/III completion, NDA/BLA approval, first commercial sale) and commercial milestones (annual sales thresholds of $100M, $500M, $1B). Total milestone potential for a major drug license can reach $500M-$1B+. - Regulatory Risk Allocation: Who bears the risk of FDA regulatory failure? If the FDA denies approval, does the licensee owe milestones contingent on approval? License agreements should specify what happens to development costs and milestone payments in regulatory failure scenarios, and whether the licensee has the right to terminate for regulatory failure and recover sunk development costs.

Certain provisions in licensing agreements reliably signal imbalance, overreach, or drafting that will disadvantage the licensee in practice. The following eight red flags should prompt careful review and negotiation — or reconsideration of the transaction — before signing. Each represents a real pattern observed in licensing agreements across technology, pharmaceutical, entertainment, and brand licensing.

Red Flag 1: Immediate Termination for Any Breach Without Cure Period (Critical). The example clause permits the licensor to terminate immediately and without notice for any breach — even minor, technical, or disputed breaches. Legitimate licensing agreements provide cure periods (typically 30-60 days) for curable breaches. Immediate termination rights without cure are appropriate only for specific, defined acts: willful IP infringement, insolvency, criminal fraud, or material safety failures — not for any breach whatsoever. A licensor with an unfettered right to terminate for any breach can weaponize technical compliance failures — a missed royalty report deadline, a minor quality control variance, a late insurance certificate — to exit an unfavorable license or extract renegotiation leverage. This provision is among the most dangerous in licensing agreements and should always be negotiated.

Red Flag 2: No Right to Updates, Improvements, or New Versions (Critical). A license to existing technology without any right to future improvements can rapidly become commercially worthless as the licensor's technology advances. If the licensed IP is software or technology that will be actively developed, the licensee needs rights to updated versions — otherwise it is paying royalties for an increasingly obsolete platform while the licensor's current customers benefit from improvements at no additional cost. Negotiate for access to updates and improvements at no additional cost for minor updates, and at specified upgrade pricing for major new versions. At minimum, negotiate for the right to access bug fixes and security patches on commercially reasonable terms.

Red Flag 3: Dispute Resolution Favoring Narrow Interpretation (High). The clause providing that "any dispute regarding scope shall be resolved in favor of the narrower interpretation" is a licensor-drafted provision that systematically disadvantages the licensee in any scope dispute. Under traditional contract interpretation principles, ambiguities in a license grant are typically resolved against the licensor (the drafter) under the doctrine of contra proferentem. A provision that inverts this principle — requiring narrow scope even in ambiguous cases — should be deleted or replaced with a neutral standard: "any ambiguity in the scope of the licenses granted in this Agreement shall be resolved by reference to the parties' mutual intent as evidenced by this Agreement as a whole and the parties' conduct during negotiation and performance."

Red Flag 4: Non-Refundable Royalties Regardless of IP Invalidity (Critical). The clause providing that royalties are non-refundable even if the licensed IP is later found invalid is a significant and one-sided risk-allocation provision. If licensed patents are invalidated through inter partes review (IPR) proceedings at the USPTO Patent Trial and Appeal Board (PTAB) — which invalidate approximately 60-70% of challenged patents — the licensee has been paying royalties for rights that did not actually exist. Under Kimble v. Marvel Entertainment (2015), royalties cannot be collected on patent claims after they expire; extending this logic, royalties collected on invalid patents should be subject to refund or credit. At minimum, negotiate for the right to suspend royalty payments and terminate the license upon final, unappealable invalidation of the licensed patents.

Red Flag 5: Unilateral Right to Modify License Terms on Short Notice (High). Some license agreements — particularly SaaS licenses with standard terms incorporated by reference via a URL — allow the licensor to modify material license terms unilaterally upon specified notice (sometimes as short as 30 days). For enterprise licenses where the licensee has built operations around specific license terms, this creates significant operational and financial risk. Negotiate for: (1) stability of material terms (royalty rates, license scope, territory, SLA commitments) requiring mutual written amendment; (2) the right to terminate without penalty if material terms change adversely; and (3) a minimum notice period of 180 days before any material change can take effect.

Red Flag 6: Licensor Can Grant Competing Licenses Despite "Exclusivity" Carve-Outs (Critical). Some license agreements describe the license as "exclusive" in the title or summary while burying carve-outs that permit competitive licenses for closely related technologies, adjacent markets, or alternative channels. Verify that the exclusivity is genuine by: (1) reviewing every carve-out from the exclusive grant and mapping them against your business plan; (2) asking the licensor to disclose all existing licenses under the licensed IP, even those the licensor characterizes as "non-competing"; and (3) ensuring that the excluded activities are genuinely outside the licensee's realistic market. A purportedly "exclusive" license with carve-outs that cover the licensee's core market is, economically, an exclusive license in name only — but still commands exclusive license royalty rates.

Red Flag 7: Overly Broad Assignment-Based Grant-Back (Critical). As discussed in Section 04, an assignment-based grant-back requiring the licensee to assign all improvements to the licensor can transfer significant value from the licensee's R&D program to the licensor. The specific red flag to look for: (a) assignment language (rather than license-back) combined with (b) a broad definition of "improvement" that could capture independently developed technology that merely "relates to," "uses," or "incorporates" the licensed IP. Any assignment-based grant-back should be rejected outright or converted to a non-exclusive license-back with explicit carve-outs for technology developed independently of the licensed IP, as demonstrated by the licensee's own development records.

Red Flag 8: Combination Product Royalty Without Apportionment (Medium). Some license agreements calculate royalties based on net sales of a "licensed product" that includes both the licensed IP and substantial non-licensed components. Without a specific apportionment provision, the royalty rate applies to the entire product price — even though the licensed IP may represent only a fraction of the product's value. Under reasonable royalty analysis in patent infringement cases (Ericsson v. D-Link, Fed. Cir. 2014; Lucent Technologies v. Gateway, Fed. Cir. 2009), courts require apportionment to the value of the patented contribution. License agreements should build in apportionment explicitly: for example, "the royalty base shall be the selling price of the Licensed Component only, not the selling price of any larger system or product of which the Licensed Component is a part."

The FAQ section below addresses twelve of the most common questions about licensing agreements, covering rights scope, royalty structures, audit rights, bankruptcy protections, IP ownership, improvement clauses, and state-specific issues. Each answer reflects legal standards as of 2026 and should be updated as the law evolves.

Q1: What is the difference between a license and an assignment of intellectual property? A license grants the right to use IP while the original owner retains title. An assignment permanently transfers ownership of the IP to the assignee under applicable federal and state law — patents require a written assignment recorded with the USPTO per 35 U.S.C. § 261; copyrights require a written instrument of conveyance per 17 U.S.C. § 204(a); trademarks are assigned along with the goodwill of the associated business. As a licensee, you have contractual rights to use the IP only during the agreement's term and within its scope — you do not own the IP and generally cannot enforce it against infringers independently (unless you hold a true exclusive license with all substantial rights). As an assignee, you own the IP outright and can modify it, relicense it, enforce it, or sell it without reference to the original owner. The choice between licensing and assignment has significant financial, legal, and tax implications: royalty income from a license is ordinary income to the licensor; proceeds from an assignment may qualify for capital gains treatment (with special rules for patent dispositions under 26 U.S.C. § 1235). Consult both IP and tax counsel before choosing between a license and an assignment structure.

Q2: Do I have royalty audit rights, and what can I audit? Most license agreements include royalty audit rights allowing the licensor to inspect the licensee's books and records to verify royalty accuracy — typically once per year upon 30-60 days written notice. Standard audit provisions entitle the licensor to review the licensee's sales records, invoicing, accounts receivable, and royalty calculation worksheets for the licensed products. Licensees should negotiate to limit audit scope to records directly relevant to royalty calculations (not general financial records), require auditors to sign confidentiality agreements, cap audit frequency at once per year absent suspected fraud, and provide that audit costs are borne by the licensor unless the audit reveals underpayment exceeding a threshold (typically 5-10% of royalties due). If an audit reveals underpayment, the licensee typically owes the underpaid amount plus interest; if the underpayment exceeds the threshold, the licensee also reimburses audit costs. Some license agreements include a "most-favored-licensee" clause ensuring the licensor will not grant lower royalty rates to future licensees without also reducing the existing licensee's rate to match.

Q3: What happens if I use licensed IP beyond the scope of my license? Use of IP outside the licensed scope is not merely a breach of contract — it constitutes independent IP infringement, triggering the licensor's enforcement rights in addition to contractual remedies. For patent licenses, unauthorized use of patented technology is literal patent infringement under 35 U.S.C. § 271, carrying the risk of enhanced damages up to treble for willful infringement (35 U.S.C. § 284) and attorneys' fees under exceptional-case doctrine (35 U.S.C. § 285). For copyright licenses, unauthorized reproduction or distribution is copyright infringement under 17 U.S.C. § 501, with statutory damages ranging from $750 to $30,000 per work, or up to $150,000 for willful infringement (17 U.S.C. § 504). The licensor can seek both breach of contract damages (including disgorgement of profits from unlicensed use) and injunctive relief to halt the out-of-scope use. If you discover that your use has exceeded the licensed scope, immediately cease the out-of-scope use, notify your attorney, and document the circumstances — early voluntary disclosure and cessation may mitigate damages exposure.

Q4: How are royalty rates typically determined in licensing negotiations? Royalty rates are negotiated based on: (1) the economic value of the licensed IP to the licensee — the "value contribution" of the licensed technology to the licensee's products; (2) industry norms for comparable licenses in the relevant technology sector; (3) the scope of the license (exclusive licenses typically command 2-5x the rate of non-exclusive licenses); (4) the licensor's cost basis and profit requirements; (5) the term and geographic scope; and (6) the licensee's projected revenue and ability to pay. In patent licensing disputes, courts and practitioners use the Georgia-Pacific factors (15 factors articulated in Georgia-Pacific Corp. v. U.S. Plywood Corp., S.D.N.Y. 1970) as a framework. For pharmaceutical licenses, the "25% rule" (allocating 25% of the licensee's expected profits to the licensor as a starting point) was used historically but has been rejected by the Federal Circuit in Uniloc USA, Inc. v. Microsoft Corp. (Fed. Cir. 2011) as unreliable without evidentiary grounding. Benchmark databases such as RoyaltySource and the Licensing Economics Review provide comparable deal data for royalty negotiations. For trademark licenses, rates are benchmarked against comparable brand licensing deals in the same product category — typically 2-5% for generic brands, 8-15% for major consumer brands, and 10-18% for entertainment character licenses.

Q5: What is a minimum royalty guarantee and how does it affect the licensee? A minimum annual royalty guarantee (MAG) is a floor payment the licensee must make regardless of actual sales. MAGs protect licensors from licensees who acquire exclusive licenses but fail to commercialize the IP — effectively blocking the market while paying nothing. For licensees, MAGs create a fixed cost that must be modeled carefully. Non-creditable MAGs (where excess royalties in a good year cannot offset the MAG in a poor year, as in the example clause above) are particularly onerous: if you sell $5M above the MAG threshold in Year 1 but only $1M below it in Year 2, you still owe the full MAG in Year 2 with no credit from Year 1. Creditable MAGs are substantially better for licensees: excess royalties in any year are credited against the MAG in future years. Negotiate for: (1) creditable MAGs; (2) MAG amounts tied to realistic commercialization projections from an agreed business plan; (3) a ramp-up period (years 1-2 with reduced or no MAG to allow for product development); (4) the right to terminate the exclusive license (converting it to non-exclusive) if the licensee cannot meet the MAG, rather than being forced to pay a MAG for exclusivity that is no longer commercially valuable; and (5) a cure period before MAG shortfalls trigger termination rights.

Q6: Does a licensor have to maintain the IP (e.g., pay patent maintenance fees) during the license term? Unless the license agreement specifies otherwise, the licensor is generally not obligated to maintain the licensed IP. If the licensor fails to pay USPTO patent maintenance fees (currently $1,600 for small entities / $3,200 for large entities at the 3.5-year stage, increasing to $7,700 / $15,400 at 11.5 years), a licensed patent lapses and enters the public domain — the licensee loses the protection of the licensed patent and the licensor's indemnity obligation may also lapse. Trademark registrations lapse if maintenance filings (Section 8 Declaration of Continued Use, Section 9 Renewal) are not timely filed. Negotiate for: (1) an express licensor obligation to maintain the licensed IP during the term, or to provide advance notice (at least 60 days) of any intended lapse; (2) a licensee right to pay maintenance fees if the licensor fails to do so, with the right to deduct those costs from royalties payable to the licensor; and (3) an automatic termination right — without penalty — if the licensor allows licensed IP to lapse without the licensee's consent.

Q7: What is a source code escrow and when should I require one? A source code escrow is an arrangement in which the software licensor deposits source code (and related documentation, build instructions, and configuration data) with a neutral third-party escrow agent. The licensee gains the right to access the source code upon defined trigger events: the licensor's bankruptcy, dissolution, cessation of business, material sustained SLA failure over a defined period (e.g., 99% uptime not achieved for 3 consecutive months), or failure to maintain or support the software for more than 60-90 days. Source code escrow is appropriate when the licensee's business operations are critically dependent on licensed software and the licensor's insolvency would prevent access to necessary updates or support. Without escrow, a licensee may be stranded with unmaintained, unsupportable software after the licensor's insolvency. Reputable escrow providers include EscrowTech International, Iron Mountain Intellectual Property Management, and NCC Group. Escrow fees range from $1,500 to $5,000 annually for deposit plus a verification service (where the escrow agent tests the completeness and buildability of the deposited code) costing $3,000-10,000 per verification. Annual verification is strongly recommended — deposits of incomplete or non-buildable source code are unfortunately common.

Q8: Can a trademark licensor lose its trademark if it does not enforce quality control? Yes — and the consequences are permanent. Under the Lanham Act (15 U.S.C. § 1051 et seq.), a trademark owner must maintain quality control over licensees' use of the mark. Failure to do so creates a "naked license" which results in trademark abandonment — the licensor permanently loses all rights in the mark. In Barcamerica Int'l USA Trust v. Tyfield Importers, Inc. (9th Cir. 2002), the Ninth Circuit held that a trademark was abandoned where the licensor had a contractual quality control provision but exercised no actual oversight — relying solely on the licensee's reputation rather than conducting inspections or product testing. In Dawn Donut Co. v. Hart's Food Stores Co. (2d Cir. 1959), the court established that trademark abandonment is not merely a defense in an infringement suit — it permanently strips the licensor of the ability to enforce the mark against anyone. From the licensee's perspective, the licensor's failure to maintain quality control can invalidate the licensee's own license — the licensee may have been paying royalties for a mark that the licensor no longer legally owns. Licensees should monitor whether their licensor is actually exercising quality control obligations and raise concerns if they observe the licensor granting licenses to parties without any apparent quality oversight.

Q9: What are the tax implications of licensing income and royalty payments? Licensing income received by a licensor is generally ordinary income subject to federal and state income tax. However, if the licensor is a U.S. corporation that developed the IP through its own R&D, the IP may qualify for special tax treatment: the Section 250 deduction (Foreign-Derived Intangible Income, FDII) reduces the effective U.S. tax rate on foreign licensing income to approximately 13.125%; the Global Intangible Low-Taxed Income (GILTI) rules under § 951A may apply to offshore licensing income earned through foreign subsidiaries. For licensees, royalty payments are generally deductible as ordinary business expenses. Transfer pricing rules (IRC § 482) require that royalties paid between affiliated companies be at arm's length, using the comparable uncontrolled transaction (CUT) method, the comparable profit method (CPM), or other approved methods under Treasury Reg. § 1.482. Cross-border licensing involves additional complexity: withholding taxes on royalties paid to foreign licensors (typically 0-30% depending on applicable tax treaty; the U.S.-UK treaty rate is 0%, while the U.S.-Japan treaty rate is 0% for related parties), OECD BEPS (Base Erosion and Profit Shifting) rules targeting IP holding structures designed to shift profit to low-tax jurisdictions, and DAC6 reporting requirements in the EU. Consult a tax attorney specializing in IP taxation before structuring any significant cross-border or related-party licensing arrangement.

Q10: What protections do I have as a licensee if the licensor goes bankrupt? Under 11 U.S.C. § 365(n) of the Bankruptcy Code, licensees of certain IP categories — patents, copyrights, and trade secrets — may elect to retain their license rights when a licensor's bankruptcy trustee rejects the license agreement as an executory contract. This election allows the licensee to: (a) continue using the licensed IP as if no rejection had occurred; (b) enforce any exclusivity provisions under the agreement; and (c) access any IP that the licensor was required to provide under the agreement. However, the licensee cannot compel the debtor to continue performing affirmative obligations (like providing support or updates) — it can only retain the right to use the IP. Regarding trademark licenses: Mission Product Holdings, Inc. v. Tempnology, LLC (S. Ct. 2019) held that a licensor's rejection of a trademark license in bankruptcy does not automatically strip the licensee of the right to use the trademark — the rejection has the same effect as a breach, not a rescission. However, § 365(n) does not explicitly cover trademarks, leaving some uncertainty. Trademark licensees should negotiate for explicit contractual § 365(n)-equivalent protections, technology escrow arrangements, and the right to continue using the mark upon the licensor's insolvency upon continued royalty payments deposited into escrow.

Q11: What is the difference between sublicensing and assigning a license? Sublicensing means the licensee grants third parties (sub-licensees) the right to exercise some or all of the licensed rights — while the licensee itself remains a party to the original license and continues to owe obligations to the licensor. The licensee is the "middle" party, responsible for both the licensor (for royalties and compliance under the original license) and the sub-licensees (for the rights granted in sublicense agreements). Assignment of a license means the licensee transfers all of its rights and obligations under the license to a third party, which then steps into the licensee's shoes. Both sublicensing and assignment typically require the licensor's prior written consent. Anti-assignment provisions in license agreements frequently include change-of-control triggers: if the licensee is acquired — even through a stock purchase rather than an asset purchase — the transaction may be deemed an "assignment" requiring licensor consent. This can be a significant issue in M&A transactions where the acquired company's license agreements are essential to its business value. Buyers should conduct IP license due diligence specifically focused on anti-assignment and change-of-control provisions, and negotiate for licensor consent to assignment as a condition of closing, or negotiate consent in advance from licensors of material licenses.

Q12: What should I do before signing a licensing agreement? The essential pre-signing checklist: (1) Verify IP ownership: Review patent ownership records at the USPTO (patent assignment database at patents.google.com), copyright registration at the U.S. Copyright Office, and trademark ownership at the USPTO TSDR database — confirm the licensor is the record owner, or that the licensor holds a valid license with sublicensing rights; (2) Confirm no prior encumbrances: Search for existing exclusive licenses (ask for disclosure), UCC financing statement filings against the licensor's IP (available through state UCC databases), and government march-in rights for Bayh-Dole IP; (3) Have an IP attorney review the grant clause: Confirm the scope of licensed acts, field of use, territory, and improvement clause — these are the provisions most commonly drafted in ways that disadvantage the licensee; (4) Model the royalty structure: Analyze minimum guarantee scenarios, Net Sales deductions, and audit rights across high/medium/low revenue projections; (5) Negotiate improvement clauses: Convert assignment-based grant-backs to non-exclusive license-backs with independent-development carve-outs; (6) Assess termination provisions: Confirm cure periods, sell-off rights, and licensor bankruptcy protections per § 365(n); (7) Review insurance requirements: Verify that the required coverage types and limits are available at commercially reasonable rates; (8) Understand dispute resolution: Evaluate whether the arbitration forum, seat, and governing law are favorable; and (9) For critical software: Negotiate for source code escrow with annual verification. Skipping even one of these steps has cost licensees millions of dollars in licensing disputes — the pre-signing investment of IP attorney time ($500-800/hour at major firms; $200-400/hour at boutique IP firms) is among the highest-ROI expenditures a licensee can make.